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In non-Hodgkin's lymphoma (NHL) an upregulation of CD44v is observed in aggressive lymphomas'0"2 and is correlated with an unfavorable clinical outcome of patients.l3. I4 Multiple myeloma (MM) represents a B-cell tumor characterized by the accumulation of neoplastic plasma cells in the bone marrow (BM). Adhesive interactions between myeloma plasma cells and BM stroma are most likely involved in the localization of myeloma cells in the BM microenvironment, the regulation of myeloma tumor growth, and the triggering of interleukin-6 (IL-6) prod~ction.'~"~ Both in murine and human plasmacytoma models, CD44 mediates one of the major adhesion pathways in tumor cell-stromal cell intera~tions.'~.'' However, these analyses have been performed using antibodies directed at CD44s epitopes, which cannot discriminate between CD44s-and CD44v-containing isoforms.
To evaluate the role of CD44v in pathogenesis and disease progression in MM, we analyzed CD44v expression in human myeloma plasma cells and myeloma-derived cell lines; furthermore, the exact exon composition was determined by reverse transcriptase-polymerase chain reaction (RT-PCR). These analyses show an overexpression of complex exon combinations in a considerable proportion of patients and an association of CD44 isoforms containing the 9v exon with an unfavorable clinical prognosis. 
MATERIALS AND METHODS

Myeloma patients and clinical data.
Sixty-four BM biopsies from 38 different myeloma patients treated at the Department of Internal Medicine, University Hospital Innsbruck (Innsbruck, Austria) were analyzed. The diagnosis of MM was established according to the criteria of the Southwest Oncology Group.'' Expression of CD44 isofoms was compared with clinical stage,'' disease activity (stable U progressive, as defined by Dune"), and survival (alive U deceased); the relevant clinical data were available in 36 patients.
In 26 patients (clinical data available in 25). sequential evaluations of CD44v expression and clinical data were performed, resulting in 61 observations. The patients' median follow-up was 38 months (range, 1 to 180 months), with a median survival of 41 months. Statistical analyses were performed by Fisher's exact test or KruskalWallis test.
Antibodies and cell lines. Monoclonal antibodies (MoAbs) directed at human CD44 epitopes used in this study were CD44-4v (1 l.lO), CD44-6v (1 1.9), CD44-9v ( I 1.24),'" CD44-3v (BBA 1 I; R & D Systems Europe, Abingdon, UK), and CD44-10v (VFF-14; Bender MedSystems, Vienna, Austria); CD44s was detected by MoAb 25.32*' or SW-2 (Bender MedSystems, Vienna, Austria). Furthermore, CD38 (Becton Dickinson, San Jose, CA) was used for the detection of plasma cells. MM-derived cell lines used in this study were RPM1 8226, IM-9, ARH-77, U266 (all obtained from the American Type Culture Collection, Rockville, MD), Fravel?' 3A  2A   ND   2A   ND  1A  3A  3A  3A  1A   3A   28   3A  3A  1A  1A  3A  2A  2A  38  38  1A   3A   1A   3A  2A  2A  3A  ND  3A  1A  1A  38  38  1A   3A   3A   3A  3A  3A  2A  2A  1A   3A   1A   3A   3A   3A   3A  3A  3A  3A   1A   1A   1A  1A  1A  1A  3A  3A  3A  3A 3A 1A and OPM-l (provided by Dr Shuichi Katagiri, Department of Medicine, Ohtemae Hospital, Osaka, Japan).
Immunohistochemical staining. Immunostaining of BM biopsies was performed as described in Eisterer et al.z3 Staining intensity was scored semiquantitatively on a scale of -to +++ (-, negative; 2 , faint, not clearly above background; +, weakly positive; ++, moderately positive; and +++, strongly positive). Myeloma cells were termed positive when greater than 20% of the tumor cells showed a reactivity of +, ++, or +++ with the relevant MoAb.
Reactivity of the MoAbs was evaluated in a semiquantitative way by two independent observers (W.E. and J.T.) without knowledge of clinical information. The evaluations of the two observers were in accordance in 95% of the analyses; in cases of discordant rating, a consensus was sought.
Fluorescence-activated cell sorting (FACS) analyses and sorting of MM cells for RT-PCR. FACS analyses were performed on BM aspirates obtained by iliac crest puncture after cell separation by Ficoll-Paque (Pharmacia LKB, Uppsala, Sweden) using a FACScan flow cytometer (Becton Dickinson). Plasma cells in myeloma samples were identified by scatter properties and expression of CD38 and analyzed using two-color immunofluorescence as described before." CD44s and CD44v expression on plasma cells was analyzed after sequential incubation with anti-CD44 MoAb, appropriate mouse isotype-specific polyclonal goat antimouse Igs coupled to fluorescein isothiocyanate (SBA, Birmingham, AL), normal mouse serum (2% in phosphate-buffered saline), and CD38-phycoerythrin. Plasma cell CD44v positivity was defined as mean fluorescence intensities at cence intensity of the plasma cells was determined by staining with an irrelevant but isotype-and subclass-matched control antibody. Myeloma plasma cells from BM aspirates were purified by high resolution cell sorting on the basis of CD38 expression and forward and orthogonal light scatter properties on a FACStar Plus (Becton Dickinson), as described before." In short, in the two-parameter dotplot projection of forward light scatter and orthogonal light scatter, an electronic plasma cell gate is created via a back-gating procedure of the bright CD38+ cells. This plasma cell gate is examined for contaminating monocytes and activated T cells (CD14+ and CD3+ Preparation of RNA and cDNA/RT-PCR. Total cellular RNA was prepared using 10' to 10' sorted myeloma plasma cells or cell lines or a cryosection from a Ki-l B-immunoblastic NHL followed by cDNA synthesis, as described recently."."' cDNA amounts were equilibrated semiquantitatively for the housekeeping gene hypoxan- The exon-specific probes were labeled with "P-dATP (Megaprime labeling kit; Amersham, Little Chalfont, UK), and blots were hybridized and washed under stringent conditions (0.2 X SSC. 0.1 % sodium dodecyl sulfate, 65°C). Blots were exposed to Kodak BioMax MR films (Eastman Kodak CO, Rochester, NY) at room temperature for 48 to 96 hours. A scheme of the CD44 gene organization indicating the exon nomenclature was reported recently.'.'' RESULTS thine phosphoribosyltransferase (HPRT) as a marker transcript. Equilibrated amounts of cDNA were taken for CD44-specific PCR CD44 isofotms in MM. Immunohistochemical expression, which was determined by exon-specific MoAbs, was restricted to a few scattered, morphologically unidentifiable BM cells (<l%) and to myeloma tumor cells. The region most frequently detected was exon 9v, which was observed in nearly half of the cases ( Table 1 and Fig ID) . In general, 9v-positive myelomas were characterized by a uniform expression of moderate or strong intensity on all tumor cells. In contrast CD44-3v-, -4v-, -6v-, and -1Ov-containing isoforms were detected in only a minority of samples and were often expressed only weakly ( Table 1 and Fig l) . All cases expressing multiple exon combinations were 9v positive (n = 11).
Correlation between CD44v expression and the clinical course of patients. CD44-9v protein expression on tumor cells in multiple analyses from 36 patients was associated with an advanced clinical stage"' ( P < .02; n = 61) and disease progression" ( P < .OOl; n = 61; Table 2 ). The death
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EtBr g e l rate was 43% (median survival, 71 months) in 9v-negative patients, as concluded from the last biopsy available; in contrast, 85% of patients in the 9v-positive group have died (median survival, 31 months; P < .02; n = 36; Table 2) .
Sequential analyses at different time points showed that monoclonal gammopathy of undetermined significance (MGUS)'" had preceded MM in 4 patients; comparison of the CD44-9v expression in MGUS and MM showed an upregulation of 9v in 2 patients (no. 34 and 38) and a downregulation in patient no. 22; 1 patient (no. 27) remained 9v negative. Considering the first and last biopsy available, patients remaining negative for 9v were often characterized by a stable disease (1 1 of 13), whereas patients constantly 9v-positive were in all cases characterized by a progressive disease (n = 5). An upregulation of 9v in the course of the disease was accompanied by progression in 3 of 4 patients.
CD44-9v expression was not correlated with the levels of
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STAUDER ET AL serum lactic acid dehydrogenase (LDH) or p 2 microglobulin (data not shown) and the distribution concerning sex and age was equivalent in the CD44-9v-negative and -positive groups. Sequential analyses in myeloma patients showed that alterations of CD44v expression were not related to the application of chemotherapy (data not shown).
Because of the low percentage of positive cases, a correlation with clinical parameters could not be established for patients positive for CD44-3v, -4v, -6v, or -1Ov. However, a highly unfavorable prognosis was observed in the 5 CD44-3v-positive patients: 4 patients suffered from progressive disease and died.
Determination of the CD44v exon composition in myeloma plasma cells and myeloma cell lines by RT-PCR. The determination of the CD44 exon composition is not possible by immunohistochemistry. Therefore, a semiquantitative RT-PCR analysis, followed by Southern blotting and detection with exon-specific probes, has been developed.'3.20 This analysis, allowing the evaluation of the isoform composition at the RNA level, was performed in myeloma cells sorted from patients' BM (Fig 2A) , in a Ki-l high-grade B-immunoblastic NHL (Fig 2B) , and in selected plasma cell lines (Fig 2B) . In parallel, the CD44v status of tumor cells was evaluated by flow cytometry (cell lines and myeloma cells) or immunohistochemical analysis (Ki-1 lymphoma).
Because CD44-9v expression is associated with an unfavorable clinical course, we determined the exon composition in 9v protein-positive tumors and compared it with 9v-negative samples. Therefore, malignant plasma cells of 4 9v-positive and 2 9v-negative myeloma patients, as established by flow cytometry, were purified by FACS sorting, and a CD44 exon-specific RT-PCR analysis was performed. At the protein level, the 9v-positive patients expressed high amounts of total CD44, as assessed by the use of an MoAb recognizing an epitope in the standard CD44 region (Fig 2A) . Furthermore, 3 of 4 9v-positive patients expressed multiple CD44 variant domains on the cell surface: patient no. 1, 6v and 9v; patient no. 2, 4v, 6v, 9v, and 1Ov; and patient no. 6, 6v and 9v. Patient no. 3 only expressed 9v. The two 9v-negative patients had low levels of total CD44 and expressed 6v and 1Ov (patient no. 4) or 1Ov protein (patient no. 5).
Considering the RNA transcripts, differences between 9v-positive and 9v-negative patients were observed. High 9v protein levels were in accordance with elevated levels of transcripts containing 9v (Fig 2A) . Furthermore, in the 9v-positive group, complex CD44 transcripts were found mainly consisting of combinations of the 3v, 6v, 7v, 8v, 9v, and 1Ov exons, ie, transcripts 6-1Ov (788 bp), 3/7-1Ov (785 bp), 7-1Ov (659 bp), 3/8-1Ov (656 bp), 8-1Ov (530 bp), or 9-1Ov (410 bp). This pattern of expression resembles the CD44 transcript heterogeneity in the high-grade malignant Ki-l NHL (Fig 2B) . In the 9v-negative patients (no. 4 and 5 ) low protein expression was paralleled by low levels of CD44 transcription. In addition, the 9v-negative patients lacked most of the large complex transcripts expressed in the 9v-positive myeloma patients and the Ki-l NHL. A highly heterogeneous CD44 expression pattern was observed in several myeloma-derived cell lines (Fig 2B) .
Fravel cells lacked CD44 at the protein and transcript level completely. OPMl was characterized by expression of CD44s domain\; correspondingly, transcript analysis showed the presence of CD44s lacking all variant exons, as assessed by the size of a 13 I-bp PCR product and hybridization with a CD44s-specific probe (Fig 2B) . Although cell lines RPMI, ARH77, IM-9, and U266 only weakly expressed CD44v at the protein level, large complex CD44v transcripts were found that were comparable to those identified in the 9v-positive patients' samples.
DISCUSSION
This study represents the first report on the expression of CD44 variant isoforms in MM and its correlation to clinical data. Moreover, the pattern of exon composition of CD44v RNA transcripts in purified BM myeloma plasma cells as well as in human myeloma cell lines as evaluated by RT-PCR is described. Immunohistochemical staining of BM biopsies of myeloma patients using antibodies against 3v, 4v, 6v, 9v, and 1Ov shows that 38% of the myeloma patients expressed CD44v on their tumor cells. The majority of these patients expressed CD44-9v (36%), whereas only a minor proportion expressed 3v, 4v, 6v, or IOv (14%, 5%, 6%, or 5%). Most importantly, the expression of variant isoforms is associated with the aggressiveness of myeloma tumors; variant isoforms containing 9v are correlated with advanced disease and an unfavorable clinical outcome, establishing 9v as a novel prognostic parameter in MM. Similarly, 3v expression in tumors is associated with an adverse clinical course, although the small number of 3v-positive patients does not allow us to generalize this observation. So far, the expression of CD44 variant isoforms in lymphoid malignancies has been described exclusively in NHL; overexpression of CD44-3v-and/or -6v-containing isoforms is shown in aggressive, high-grade malignant lymphomas""" and is associated with an unfavorable clinical
In contrast, 9v expression is a rare event in N H L ,~? .~~ suggesting differences in CD44 splicing during disease progression in MM and NHL. In accordance with the close association of 9v expression with prognosis in MM, 9v is associated with an adverse prognosis in gastric carcinoma^'^ and with an unfavorable tumor grade in renal cell carcinomas." Thus, 9v might mediate a general mechanism involved in tumor progression, as has been suggested by Galluzo et al.26 To analyze and compare the composition of CD44v RNA transcripts in 9v-positive and 9v-negative myelomas, an RT-PCR approach was applied on FACS-purified plasma cells, followed by Southern blotting with exon-specific probes.".'" Consistent with the pattern of protein expression, transcript combinations of 3v and 9v were detected most frequently. CD44-9v protein-positive myeloma patients expressed large complex CD44 transcripts consisting mainly of combinations of 3v and exons 6-1 Ov. Similar exon combinations have so far been observed in rare cases of aggressive NHL (Salles et al," Stauder et a1,l3 and this study), in several myeloma cell lines (this study), in rare subtypes of myeloid and lymphoid leukemias (U. Gunthert, manuscript in preparation), and in renal cell carcinomas." In contrast, these large transcripts could not be detected in the two 9v protein-negative myelomas analyzed, suggesting a correlation between use only. and high-grade NHL13; however, 3/6-10v transcription in T cells is rapidly downregulated after a few hours.13 In contrast, the appropriate downregulation of variant transcripts might be disturbed in MM, resulting in a prolonged and untimely expression similar to the expression pattern of the receptor for hyaluronan-mediated m~tility.~' It is known that the ras oncogene can modulate alternative CD44 spli~ing.~',.'~ Because ras mutations accumulate during disease progre~sion~~ and are associated with an autonomous IL-6-independent growth of plasmacytoma cells,34 one might speculate that ras proto-oncogene activation and CD44-9v upregulation in MM are correlated.
By which mechanisms might altered CD44v expression influence tumor behavior in MM? The direct pathogenic role of distinct CD44 splice variants in the dissemination of lymphoid neoplasms has been elucidated recently. Transfected lymphomas expressing large 9v containing isoforms, particularly 3-1Ov and 3/8-10v, showed a slow subcutaneous growth in an animal model7; however, intravenous injection resulted in a preferential dissemination to and growth in the BM and, in accordance with our observations in MM (this study), in a worse prognosis in comparison with isoforms containing only the standard region.' Because functional analyses performed by Bartolazzi et a17 were restricted to the examination of binding to lymph node stromal cells, the cellular mechanisms of enhanced BM infiltration remain ambiguous. Hypothetically, distinct variant isoforms may recognize ligands that facilitate homing to the BM. Alternatively, CD44v-expressing cells might be preferentially stimulated within this microenvironment. The glycosaminoglycan HA represents the principle known ligand for CD44.2,35,36 By influencing intercellular interactions and anchoring processes, HA binding to CD44 regulates lymphop~iesis~~ and plasmacytoma growth." The presence of CD44v sequences modifies the HA binding activity of the CD44 m o l e c~l e .~~~* Furthermore, CD44v molecules, including those that contain 6v and 9v, can indirectly increase cellular HA binding as a consequence of cellular activation.26 Thus, different CD44v isoforms might alter the behavior of myeloma cells by mediating cellular activation" or by influencing CD44-HA interactions relevant for MM growth, such as stromal cell bindingI6,'' or IL-6 prod~ction. ' 
